Leslie RD, Palmer J, Schloot NC, Lernmark A. Diabetes at the crossroads: relevance of ailment classification to pathophysiology and treatment. Diabetologia. 24 October 201five [Epub ahead of print]
Grant SFA, Hakonarson H, Schwartz S. Can easily the genetics of type 1 and type 2 diabetes gone light on the genetics of latent autoimmune diabetes in adults? Endocr Rev 2010;31:183–193
Rolandsson O, Palmer JP. Latent autoimmune diabetes in adults (LADA) is dead: long live autoimmune diabetes! Diabetologia 2010;53:1250–1253
Redondo MJ. LADA: time for a brand-new definition. Diabetes 2013;62:339–340
Basile KJ, Guy VC, Schwartz S, Grant SFA. Overlap of genetic susceptibility to type 1 diabetes, type 2 diabetes, and latent autoimmune diabetes in adults. Curr Diab Rep 2014;14:550
Thomas CC, Philipson LH. Update on diabetes classification. Med Clin North Am 2015;99:1–16
Polsky S, Ellis SL. Obesity, insulin resistance, and type 1 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2015;22:277–282
Guy VC, Chesi A, Hawa M, et al. The role of GWAS-implicated type 1 and type 2 diabetes loci in the pathogenesis of latent autoimmune diabetes in adults (LADA) (Abstract) Diabetes 2015;64(Suppl. 1):A80
Corkey BE. Diabetes: have actually we got it all of wrong? Insulin hypersecretion and meals additives: induce of obesity and type 2 diabetes? Diabetes Care 2012;35:2432–2437
Guglielmi C, Palermo A, Pozzilli P. Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy. Diabetes Metab Res Rev 2012;28(Suppl. 2):40–46
Ghazi T, Rink L, Sherr JL, Herold KC. Acute metabolic effects of exenatide in patients along with type 1 diabetes along with and devoid of residual insulin to oral and intravenous glucose challenges. Diabetes Care 2014;37:210–216
Lebovitz HE. Adjunct therapy for type 1 diabetes mellitus. Nat Rev Endocrinol 2010;6:326–334
Munir KM, Davis SN. The treatment of type 1 diabetes mellitus along with agents approved for type 2 diabetes mellitus. Expert Opin Pharmacother 2015;16:2331–2341
Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic regulate in type 1 diabetes: outcomes of an 8-week open-label proof-of-idea trial. Diabetes Care 2014;37:1480–1483
Renukuntla VS, Ramchandani N, Trast J, Cantwell M, Heptulla RA. Role of glucagon-adore peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop establishing along with ePID algorithm. J Diabetes Sci Technol 2014;8:1011–1017
Tafuri KS, Godil MA, Lane AH, Wilson TA. Effect of pioglitazone on the road of newonset type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol 2013;5:236–239
Zhao Y, Yang L, Xiang Y, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains b-cell function in patients along with recent-onset latent autoimmune diabetes in adults: one year prospective study. J Clin Endocrinol Metab 2014;99:E876–E880
Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients along with type 2 diabetes. Diabetes Obes Metab 2008;10:376–386
Abdul-Ghani MA, Puckett C, Triplitt C, et al. Very first combination therapy along with metformin, pioglitazone and exenatide is much more efficient compared to sequential add-on therapy in subjects along with new-onset diabetes. outcomes from the Efficacy and Durability of Very first Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab 2015;17:268–275
Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose regulate along with addition of exenatide or sitagliptin to combination therapy along with insulin glargine and metformin: a proof-of-idea study. Diabetes Care 2010;33:1509–1515
Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients along with type 2 diabetes. Diabetes Res Clin Pract 2008;79:291–298
Schwartz S. Evidence-based method usage of incretin-based therapy in the natural history of diabetes. Postgrad Med 2014;126:66–84
Schwartz SS, DeFronzo RA, Umpierrez GE. Useful implementation of incretin-based therapy in hospitalized patients along with type 2 diabetes. Postgrad Med 2015;127:251–257
Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardio outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128
Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015;38:412–419
Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S; Dapagliflozin 00six Study Group. Dapagliflozin in patients along with type 2 diabetes receiving higher doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 2014;16:124–136
Anık A, Çatlı G, Abacı A, Böber E. Maturityonset diabetes of the young (MODY): an update. J Pediatr Endocrinol Metab 2015;28:251–263
Longo N, Wang Y, Pasquali M. Progressive decline in insulin levels in Rabson-Mendenhall syndrome. J Clin Endocrinol Metab 1999;84:2623–2629
Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a brand-new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773–795
Kunutsor SK, Apekey TA, Laukkanen JA. Association of serum total osteocalcin along with type 2 diabetes and intermediate metabolic phenotypes: systematic review and meta-analysis of observational evidence. Eur J Epidemiol 2015;30:599–614
DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a brand-new road to normalizing glycaemia. Diabetes Obes Metab 2012;14:5–14
Pietropaolo M, Barinas-Mitchell E, Kuller LH. The heterogeneity of diabetes: unraveling a dispute: is systemic inflammation related to islet autoimmunity? Diabetes 2007;56:1189–1197
Subauste A, Gianani R, Chang AM et al. Islet autoimmunity identifies a unique pattern of impaired pancreatic beta-cell function, markedly low pancreatic beta cell mass and insulin resistance in clinically diagnosed type 2 diabetes. PLoS One 2014;9:e106537
Oslowski CM, Hara T, O’Sullivan-Murphy B, et al. Thioredoxin-interacting healthy protein mediates ER stress-induced b cell death through initiation of the inflammasome. Cell Metab 2012;16:265–273
Chaudhuri A, Ghanim H, Vora M, et al. Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab 2012;97:198–207
Makdissi A, Ghanim H, Vora M, et al. Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab 2012;97:3333–3341
Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2014;383:1068–1083
Allin KH, Nielsen T, Pedersen O. Mechanisms in endocrinology: gut microbiota in patients along with type 2 diabetes mellitus. Eur J Endocrinol 2015;172:R167–R177
Tai N, Wong FS, Wen L. The role of gut microbiota in the improvement of type 1, type 2 diabetes mellitus and obesity. Rev Endocr Metab Disord 2015;16:55–65
Carvalho BM, Saad MJ Influence of gut microbiota on subclinical inflammation and insulin resistance. Mediators Inflamm 2013;2013:986734
Del Prato S. Role of glucotoxicity and lipotoxicity in the pathophysiology of type 2 diabetes mellitus and emerging treatment strategies. Diabet Med 2009;26:1185–1192
Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005;90:501–506
Iwakura T, Fujimoto S, Kagimoto S, et al. Sustained enhancement of Ca(2+) influx by glibenclamide causes apoptosis in RINm5F cells. Biochem Biophys Res Commun 2000;271:422–428
Reimer MK, Holst JJ, Ahrén B. Lasting inhibition of dipeptidyl peptidase IV enhances glucose tolerance and preserves islet function in mice. Eur J Endocrinol 2002;146:717–727
Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 along with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006;55:1695–1704
Chen J, Couto FM, Minn AH, Shalev A. Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun 2006;346:1067–1074
Shimoda M, Kanda Y, Hamamoto S, et al. The human glucagon-adore peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum pressure in a mouse model of diabetes. Diabetologia 2011;54:1098–1108
Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov 2014;13:465–476
Roep BO, Tree TI. Immune modulation in humans: implications for type 1 diabetes mellitus. Nat Rev Endocrinol 2014;10:229–242
Rossetti L, Hawkins M, Chen W, Gindi J, Barzilai N. In vivo glucosamine infusion causes insulin resistance in normoglycemic yet not in hyperglycemic conscious rats. J Clin Invest 1995;96:132–140
Straub RH. Insulin resistance, selfish brain, and selfish immune system: an evolutionarily positively chosen regimen used in chronic inflammatory diseases. Arthritis Res Ther 2014;16(Suppl. 2):S4
Simmons AL, Schlezinger JJ, Corkey BE. Exactly what are we placing in our meals that is making us fat? meals additives, contaminants, and others putative contributors to obesity. Curr Obes Rep 2014;3:273–285
Erion KA, Berdan CA, Burritt NE, Corkey BE, Deeney JT. Chronic exposure to excess nutrients left-shifts the concentration dependence of glucose-stimulated insulin secretion in pancreatic beta cells. J Biol Chem 2015;290:16191–16201
Halban PA, Polonsky KS, Bowden DW, et al. b-Cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care 2014;37:1751–1758
Stähli BE, Gebhard C, Tardif JC. Lipid effects and cardio ailment risk associated along with glucose-lowering medications. Curr Cardiol Rep 2015;17:608
ChevalierN, Fénichel P. Endocrine disruptors: brand-new gamers in the pathophysiology of type 2 diabetes? Diabetes Metab 2015;41:107–115
Escobedo G, López-Ortiz E, Torres-Castro I. Gut microbiota as a vital user in triggering obesity, systemic inflammation and insulin resistance. Rev Invest Clin 2014;66:450–459
Biswas SK, Mohtarin S, Mudi SR, et al. Partnership of soluble RAGE along with insulin resistance and beta cell function throughout improvement of type 2 diabetes mellitus. J Diabetes Res 2015;2015:150325
Raciti GA, Longo M, Parrillo L, et al. Learning type 2 diabetes: from genetics to epigenetics. Acta Diabetol 2015;52:821–827
Zhao M, Wang Z, Yung S, Lu Q. Epigenetic dynamics in immunity and autoimmunity. Int J Biochem Cell Biol 2015;67:65–74
Schlaich M, Straznicky N, Lambert E, Lambert G. Metabolic syndrome: a sympathetic disease? Lancet Diabetes Endocrinol 2015;3:148–157
Coomans CP, van den Berg SA, Lucassen EA, et al. The suprachiasmatic nucleus controls circadian power metabolism and hepatic insulin sensitivity. Diabetes 2013;62:1102–1108
Mandrup-Poulsen T. IAPP enhances islet macrophage IL-1 in type 2 diabetes. Nat Immunol 2010;11:881–883
Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 2003;52:1–8
Gottlieb PA. Exactly what defines ailment in an age of genetics and biomarkers? Curr Opin Endocrinol Diabetes Obes 2015;22:296–299
Groop L, Storm P, Rosengren A. Can easily genetics increase precision of therapy in diabetes? Trends Endocrinol Metab 2014;25:440–443
Zhou K, Donnelly L, Yang J, et al.; Wellcome Trust Case regulate Consortium 2. Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diabetes Endocrinol 2014;2:481–487
Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The lots of faces of diabetes: a ailment along with increasing heterogeneity. Lancet 2014;383:1084–1094
Wherrett DK, Chiang JL, Delamater AM, et al.; Type 1 Diabetes TrialNet Study Group. Defining pathways for improvement of disease-modifying therapies in youngsters along with type 1 diabetes: a consensus report. Diabetes Care 2015;38:1975–1985
Armato J, DeFronzo RA, Abdul-Ghani M, Ruby R. Successful treatment of prediabetes in clinical practice: targeting insulin resistance and b-cell dysfunction. Endocr Pract 2012;18:342–350
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Update to a placement statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429–442
Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract 2015;21:438–447
DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients along with newly diagnosed type 2 diabetes. Diabetes Care 2013;36(Suppl. 2):S127–S138
Federal Drug Administration. Code of Federal Regulations Title 21. Sec. 310.517: Labeling for oral hypoglycemic drugs of the sulfonylurea class, 49 FR 14331, 11 April 1984. Available from http://ift.tt/1TNwIm1. Accessed twenty September 2015
Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and side cardio outcomes in type 2 diabetes: a comparison of patients treated along with sulfonylureas and metformin. Diabetologia 2006;49:930–936
Margolis DJ, Hoffstad O, Strom BL. Association between significant ischemic cardiac outcomes and medications used to manage diabetes. Pharmacoepidemiol Drug Saf 2008;17:753–759
Currie CJ, Johnson JA. The safety profile of exogenous insulin in individuals along with type 2 diabetes: justification for concern. Diabetes Obes Metab 2012;14:1–4
Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes regulate and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardio ailment in patients along with type 1 diabetes. N Engl J Med 2005;353:2643–2653
Draznin B. Mechanism of the mitogenic influence of hyperinsulinemia. Diabetol Metab Syndr 2011;3:10
Karlstad O, Starup-Linde J, Vestergaard P, et al. usage of insulin and insulin analogs and risk of cancer – systematic review and metaanalysis of observational studies. Curr Drug Saf 2013;8:333–348
Yarchoan M, Arnold SE. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 2014;63:2253–2261
Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev 2015;95:727–748
Kelly CT, Mansoor J, Dohm GL, Chapman WH 3rd, Pender JR 4th, Pories WJ. Hyperinsulinemic syndrome: the metabolic syndrome is broader compared to you think. Surgery 2014;156:405–411
Kleinridders A, Ferris HA, Cai W, Kahn CR. Insulin action in brain regulates systemic metabolism and brain function. Diabetes 2014;63:2232–2243
Muntoni S, Muntoni S. Insulin resistance: pathophysiology and rationale for treatment. Ann Nutr Metab 2011;58:25–36
Riddle M, Frias J, Zhang B, et al. Pramlintide improved glycemic regulate and low weight in patients along with type 2 diabetes using basal insulin. Diabetes Care 2007;30:2794–2799
Garber AJ, King AB, Del Prato S, et al.; NN1250-3582 (Start BB T2D) Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment along with mealtime insulin aspart in type 2 diabetes (Start Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target noninferiority trial. Lancet 2012;379:1498–1507
Matthews D, Fulcher G, Perkovic V, et al. Efficacy and safety of canagliflozin, an inhibitor of sodiumglucose co-transporter 2, added on to insulin therapy along with or devoid of oral agents in type 2 diabetes. Poster presented at the 48th Annual Meeting of the European Association for the Study of Diabetes, 1–five October 2012, Berlin, Germany
Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517–1526
